目的 探討益血生膠囊聯(lián)合兔抗人胸腺細(xì)胞免疫球蛋白治療再生障礙性貧血的臨床療效。方法 選取2015年6月-2016年6月天津市第五中心醫(yī)院收治的再生障礙性貧血患者126例，隨機(jī)分成對照組（63例）和治療組（63例）。對照組患者靜脈滴注兔抗人胸腺細(xì)胞免疫球蛋白，2.5 mg/kg加入生理鹽水250 mL，滴注時長>4 h，1次/d，連續(xù)治療5 d。治療組患者在對照組基礎(chǔ)上口服益血生膠囊，4粒/次，3次/d。兩組患者均治療5 d。觀察兩組患者臨床療效，同時比較治療前后兩組患者血象指標(biāo)、免疫指標(biāo)和不良反應(yīng)。結(jié)果 治療后，對照組臨床有效率為82.54%，顯著低于治療組的96.82%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者的白細(xì)胞計數(shù)、血小板計數(shù)和血紅蛋白水平均顯著升高（P<0.05），且治療組患者上述指標(biāo)明顯高于對照組（P<0.05）。治療后，兩組患者CD4⁺計數(shù)顯著升高（P<0.05），CD8⁺計數(shù)顯著降低（P<0.05），且治療后治療組患者上述免疫指標(biāo)明顯好于對照組（P<0.05）。治療期間，對照組患者不良反應(yīng)發(fā)生率為20.63%，顯著高于治療組患者的6.35%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 益血生聯(lián)合兔抗人胸腺細(xì)胞免疫球蛋白治療再生障礙性貧血療效顯著，安全性高，具有一定的臨床推廣應(yīng)用價值。

Objective To discuss the clinical effect of Yixuesheng Capsules combined with Rabbit Anti-human Thymocyte Immunoglobulin in treatment of aplastic anemia. Methods Patients (126 cases) with aplastic anemia in Tianjin Fifth Central Hospital from June 2015 to June 2016 were randomly divided into control (63 cases) and treatment (63 cases) groups. Patients in the control group were iv administered with Rabbit Anti-human Thymocyte Immunoglobulin, 2.5 mg/kg added into normal saline 250 mL, continuous instillation >4 h, once daily, and they were treated for 5 d. Patients in the treatment group were po administered with Yixuesheng Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 5 d. After treatment, the clinical efficacy was evaluated, and the hematological parameters, the immunological indexes, and the adverse reactions two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 82.54%, which was significantly lower than 96.82% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the leucocyte count, platelet count and hemoglobin level in two groups were significantly increased (P<0.05), and these indexes in the treatment group after treatment were significantly higher than those in the control group (P<0.05). After treatment, the CD4⁺ count in two groups were significantly increased (P<0.05), the CD8⁺ count were significantly decreased (P<0.05), and the immunological indexes in the treatment group after treatment were significantly better than those in the control group (P<0.05). During the treatment, the adverse reactions rate in the control group was 20.63%, which was significantly higher than 6.35% in the treatment group, with significant difference between two groups (P<0.05). Conclusion Yixuesheng Capsules combined with Rabbit Anti-human Thymocyte Immunoglobulin has significant curative effect in treatment of aplastic anemia with high safety, which has a certain clinical application value.